European biotech MorphoSys AG has a potential blockbuster on its hands, and with a US Food and Drug Administration filing just weeks away, its new CEO is on the hunt for a commercial partner to help maximise the drug’s potential.
Tafasitamab (formerly MOR208) is a next-generation antibody, dubbed by some a possible "CAR-T killer" in the diffuse large B-cell lymphoma...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

